About Delcath

Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Our proprietary product-Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan HDS)-is designed to administer high dose chemotherapy to the liver, while controlling the systemic exposure to those agents. The Company's principal focus is on the treatment of primary and metastatic liver cancers. In the United States, the Melphalan/HDS system is considered a combination drug and device product, and is regulated as a drug by the United States Food and Drug Administration (FDA). The Melphalan/HDS system has not been approved for sale in the United States. In Europe, our proprietary system to deliver and filter melphalan hydrochloride is marketed as a device under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT). In April 2012, we obtained authorization to affix a CE Mark for the Generation Two CHEMOSAT system. The right to affix the CE mark allows the Company to market and sell the CHEMOSAT system in Europe. The Company has initiated plans to investigate the Melphalan/HDS system for primary liver cancer.

History

Delcath has spent many years researching ways to administer ultra-high doses of established chemotherapeutic drugs to the liver.

See All History

Management Team

Barbra C. Keck

Barbra C. Keck

Vice President, Controller & Principal Accounting Officer

Meet the Rest of the Management Team

Medical Advisory Board

Alexander M. M. Eggermont, MD, PhD

Alexander M. M. Eggermont, MD, PhD

Institut Gustave Roussy

Meet the Rest of the Medical Advisory Board

Related Links

Board of Directors
Corporate Governance